Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 2,798 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Light Clear all
Completed Not applicable Interventional

Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris

NCT03303170
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sebacia Microparticles, Nd:Yag Laser
Device
Lead sponsor
Sebacia, Inc.
Industry
Eligibility
12 Years to 45 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Scottsdale, Arizona • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

NCT01222715
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma
Interventions
Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis, Temsirolimus, Vinorelbine Tartrate
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 29 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
163
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 22, 2026, 6:23 PM EDT
Recruiting Phase 2 Interventional

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

NCT07504588
View directory record Official record
Conditions
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Sacituzumab Govitecan
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02853318
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis, Pembrolizumab
Biological · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Not applicable Interventional

Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy

NCT03799523
View directory record Official record
Conditions
Breast Cancer
Interventions
Temporary skin markings, Surface imaging
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 22, 2026, 6:23 PM EDT
Terminated Not applicable Interventional Results available

Maximizing the Initial Experience of a Neophyte Scleral Lens Wearer

NCT04583579
View directory record Official record
Conditions
Contact Lens Adaptation
Interventions
DMV inserter (DMV® MagicTouch™) with an open end, DMV inserter (DMV® MagicTouch™) with a closed end, Three fingers (Patient's Hand), O-ring (Hardware Store Product), Tea light candle (Generic Deparment Store Product) with DMV inserter (DMV® MagicTouch™)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 22, 2026, 6:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

NCT00977574
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
Interventions
Bevacizumab, Carboplatin, Ixabepilone, Laboratory Biomarker Analysis, Paclitaxel, Temsirolimus
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
230
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 163 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Not applicable Interventional Results available

A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)

NCT03687970
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Brief Pain Inventory, Hospital Anxiety and Depression Scale, Neuropathic Pain Symptom Inventory, Diode Laser fiber type Selective Stimulator, Quantitative sensory testing, Conditioned pain modulation efficiency, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)
Other · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Not applicable Interventional

IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms

NCT06094608
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Morning light treatment, Treatment-as-usual
Device · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 6:23 PM EDT
Recruiting Phase 2 Interventional

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

NCT06288113
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a

NCT02772068
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Istaroxime, Exercise
Drug · Other
Lead sponsor
Benjamin Levine
Other
Eligibility
60 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Not applicable Interventional Results available

Effects of Reducing Indoor Air Pollution on the Adult Asthmatic Response

NCT02153359
View directory record Official record
Conditions
Asthma
Interventions
High Efficiency Particulate Air Cleaner, Sham air cleaner
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 22, 2026, 6:23 PM EDT
Terminated Not applicable Interventional Results available

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

NCT00724061
View directory record Official record
Conditions
Lymphoma
Interventions
Pegylated interferon α-2b, Psoralens with ultraviolet light A, Narrowband-ultraviolet light B
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 22, 2026, 6:23 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Advanced Ultrasound Signal Processing of Suspicious Breast Images

NCT07206888
View directory record Official record
Conditions
Breast Cancer, Breast Cyst, Microcalcification
Interventions
Imaging
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2037
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 2 Interventional Results available

Hyperbaric Oxygen Effects on Persistent Post-concussive Symptoms

NCT05173818
View directory record Official record
Conditions
Persistent Post-concussive Syndrome, Concussion Post Syndrome
Interventions
Hyperbaric oxygen at 1.5 ATA, Sham treatment
Drug
Lead sponsor
Essentia Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Light Sleep: Screen Use and Sleep Health

NCT05342662
View directory record Official record
Conditions
Glasses
Interventions
Blue light-blocking glasses, Glasses with clear lenses
Device
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 29 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

NCT04797793
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.1%, Placebo Control, Differin® Gel (Adapalene 0.1%, Galderma)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
978 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 22, 2026, 6:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Hydration Status on Substrate Oxidation at Rest and During Light and Moderate Exercise

NCT07298863
View directory record Official record
Conditions
Hydration Status, Substrate Metabolism During Exercise
Interventions
Part 1 - Exercise Trial, Part 1 - Experimental Trial, Part 2 - Oral Glucose Tolerance Test
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 6:23 PM EDT
Active, not recruiting No phase listed Observational

Clinical Markers of Dysphagia in Cardiac Surgical Patients

NCT05304416
View directory record Official record
Conditions
Cardiovascular Diseases, Dysphagia
Interventions
Fiberoptic Endoscopic Evaluation of Swallowing, Simultaneous FEES and Videofluoroscopy instrumental swallowing exam, Videofluoroscopy instrumental swallowing exam (VFSS), Voluntary Cough Peak Expiratory Flow (PEF) Testing, Reflex Cough Screen, Lingual Pressure Testing, Speech Testing
Diagnostic Test · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

NCT02700230
View directory record Official record
Conditions
Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1, Recurrent Malignant Peripheral Nerve Sheath Tumor
Interventions
Computed Tomography, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Quality-of-Life Assessment, Single Photon Emission Computed Tomography, Magnetic Resonance Imaging, Ultrasound Imaging, Biospecimen Collection, Biopsy, Questionnaire Administration
Procedure · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 22, 2026, 6:23 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor

NCT06293638
View directory record Official record
Conditions
Essential Tremor
Interventions
Alcohol, Alprazolam, Cold Therapy, Peripheral Nerve Stimulation
Drug · Device · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
30 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 6:23 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Effect of ACT and Float REST on Burnout Syndrome.

NCT03535493
View directory record Official record
Conditions
Burnout Syndrome
Interventions
Acceptance and Commitment Therapy (ACT), Float REST, ACT + Float REST
Behavioral
Lead sponsor
Amrinder Babbra
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Saint Charles, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 22, 2026, 6:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Household Air Quality in Homes With Children

NCT01634334
View directory record Official record
Conditions
Lung Diseases, Asthma
Interventions
Real-Time Intervention, Usual Education
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 22, 2026, 6:23 PM EDT
Not listed No phase listed Observational

ICG Angiogram as a Predictor of Postoperative Visual Function After EEA Surgery

NCT06501716
View directory record Official record
Conditions
Indocyanine Green, Skull Base Neoplasms
Interventions
Indocyanine Green
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 22, 2026, 6:23 PM EDT